JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Community-based Intervention Effects on Older Adults' Physical Activity

  NCT03326141

  Conditions:   Exercise;   Physical Activity;   Accidental Fall;   Motivation;   Older Adults
  Interventions:   Behavioral: Otago Exercise Program;   Device: Physical activity monitors (e.g., Fitbit);   Behavioral: Interpersonal Behavior Change Strategies;   Behavioral: Intrapersonal Behavior Change Strategies;   Other: Information about Health and Wellness
  Sponsors:   University of Minnesota;   National Institute of Nursing Research (NINR)
  Recruiting
• Concurrent Aerobic Exercise and Virtual Reality Cognitive Training

  NCT02963415

  Condition:   Preclinical Alzheimer's Disease
  Intervention:   Behavioral: Exergame
  Sponsor:   University of Minnesota
  Recruiting
• The ACT Trial: Effects of Combined Aerobic Exercise and Cognitive Training in MCI

  NCT03313895

  Condition:   Mild Cognitive Impairment
  Interventions:   Behavioral: ACT;   Behavioral: Cycling Only;   Behavioral: Cognitive Training Only;   Behavioral: Stretching and Mental Stimulating Activities
  Sponsors:   University of Minnesota;   University of Rochester;   Mayo Clinic;   University of St Thomas
  Recruiting
• Post-contracture Release Radiation for Dupuytren's Disease

  NCT04122313

  Conditions:   Dupuytren's Disease;   Dupuytren Contracture;   Dupuytren Disease of Palm and Finger;   Dupuytren Disease of Finger;   Dupuytrens Contracture of Both Hands;   Dupuytren's Disease of Palm of Right Hand;   Dupuytren's Disease of Palm of Left Hand;   Dupuytren Contracture of Right Palm;   Dupuytren Contracture of Left Palm;   Dupuytren's Contracture Left;   Dupuytren's Contracture Right
  Intervention:   Other: Evaluation of Dupuytren's Disease Treatment
  Sponsor:   University of Minnesota
  Recruiting
• Traumatic Nightmares Treated by NightWare (To Arouse Not Awaken)

  NCT04040387

  Conditions:   Stress Disorders, Post-Traumatic;   Combat Disorders;   Ptsd;   Nightmare;   Nightmares, REM-Sleep Type;   Nightmare Disorder With Associated Non-Sleep Disorder
  Interventions:   Device: NightWare Therapeutic System;   Device: Sham NightWare
  Sponsors:   NightWare;   Minneapolis Veterans Affairs Medical Center
  Recruiting
• Problem-Solving Therapy for Depressive Symptoms and Quality of Life in Stroke Survivor-Caregiver Dyads

  NCT04035681

  Conditions:   Stroke;   Quality of Life;   Depression
  Interventions:   Behavioral: Problem-Solving Therapy;   Other: Stroke-Related Health Education
  Sponsors:   Allina Health System;   University of Minnesota
  Recruiting
• Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

  NCT04032301

  Conditions:   Post-Traumatic Stress Disorders;   Major Depressive Disorder
  Interventions:   Drug: Ketamine;   Other: Normal Saline
  Sponsors:   University of Minnesota;   Minneapolis Veterans Affairs Medical Center
  Recruiting
• IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

  NCT04028960

  Condition:   Type1diabetes
  Interventions:   Drug: Regular insulin (Humulin-R), intranasal route;   Device: SipNose intranasal device
  Sponsors:   HealthPartners Institute;   International Diabetes Center at Park Nicollet;   Juvenile Diabetes Research Foundation
  Recruiting
• FT516 in Subjects With Advanced Hematologic Malignancies

  NCT04023071

  Conditions:   Acute Myelogenous Leukemia;   B-cell Lymphoma
  Interventions:   Drug: FT516;   Drug: Rituximab;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: IL-2
  Sponsor:   Fate Therapeutics
  Recruiting
• Cf-DNA Assay During Treatment of Acute Rejection

  NCT04019353

  Conditions:   Kidney Transplant Failure and Rejection;   Kidney Transplant; Complications;   Kidney Transplant Rejection;   Transplant; Complication, Rejection;   Transplant Dysfunction
  Intervention:   Genetic: cf-DNA Collection
  Sponsor:   University of Minnesota
  Recruiting
• Allogeneic Skin Grafting

  NCT04015947

  Condition:   GVHD
  Intervention:   Device: CelluTome® Epidermal Harvesting System
  Sponsor:   University of Minnesota
  Recruiting
• State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S

  NCT04011449

  Conditions:   Parkinson Disease;   Parkinson
  Intervention:   Device: Medtronic RC+S DBS system
  Sponsor:   University of Minnesota
  Recruiting
• Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa

  NCT04007900

  Conditions:   Anorexia Nervosa;   Anorexia
  Intervention:   Behavioral: Positive Affect Treatment
  Sponsor:   University of Minnesota
  Recruiting
• Hepatic Energy Fluxes in NASH and NAS Patients

  NCT03997422

  Conditions:   NASH - Nonalcoholic Steatohepatitis;   NAS;   Overweight or Obesity;   Weight Loss;   Bariatric Surgery Candidate
  Intervention:   Procedure: Vertical Sleeve Gastrectomy (VSG)
  Sponsor:   University of Minnesota
  Recruiting
• Algorithms for Programming DBS Systems for ET

  NCT03984643

  Condition:   Essential Tremor
  Intervention:   Device: Vim-Deep Brain Stimulation
  Sponsor:   University of Minnesota
  Recruiting
• Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

  NCT03981705

  Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer
  Intervention:   Radiation: Standard Trimodality Breast Imaging
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Low Sulfur Fecal Transplant for Ulcerative Colitis

  NCT03948919

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Fecal microbiota;   Other: Placebo
  Sponsor:   University of Minnesota
  Recruiting
• Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

  NCT03942653

  Condition:   Salivary Gland Carcinoma
  Interventions:   Drug: Goserelin Acetate;   Drug: Pembrolizumab
  Sponsors:   Big Ten Cancer Research Consortium;   Merck Sharp & Dohme Corp.;   TerSera Therapeutics
  Recruiting
• Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer

  NCT03934840

  Condition:   Prostate Cancer
  Interventions:   Drug: Cabazitaxel;   Drug: Carboplatin;   Drug: Abiraterone;   Drug: Prednisone
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Training for Health Professionals In Tanzania

  NCT03923582

  Conditions:   Health Knowledge, Attitudes, Practice;   Training
  Intervention:   Behavioral: Health Curriculum Training
  Sponsors:   University of Minnesota;   Muhimbili University of Health and Allied Sciences;   Johns Hopkins University
  Recruiting
• The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

  NCT03921658

  Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
  Intervention:  
  Sponsors:   University of Minnesota;   United States Department of Defense
  Recruiting
• Care to Plan: a Tailored Resource for Family Members of Persons With Dementia

  NCT03901456

  Conditions:   Dementia;   Alzheimer Disease;   Memory Loss
  Interventions:   Behavioral: Care to Plan;   Behavioral: Usual Care
  Sponsors:   University of Minnesota;   National Institute on Aging (NIA)
  Recruiting
• Adoptive Transfer of Haploidentical NK Cells and N-803

  NCT03899480

  Conditions:   Hiv;   HIV Infections;   Immune Deficiency
  Intervention:   Biological: Haploidentical Natural Killer (NK) Cells
  Sponsor:   University of Minnesota
  Recruiting
• Immunologic Effects of Radioembolization of Primary and Secondary Liver Malignancies

  NCT03889093

  Conditions:   Hepatocellular Carcinoma;   Secondary Malignant Neoplasm of Liver
  Intervention:   Other: Yttrium-90
  Sponsor:   University of Minnesota
  Recruiting
• Advanced Reperfusion Strategies for Refractory Cardiac Arrest

  NCT03880565

  Conditions:   Cardiac Arrest;   Extracorporeal Membrane Oxygenation Complication;   Ventricular Fibrillation;   Pulseless Ventricular Tachycardia;   Out-Of-Hospital Cardiac Arrest
  Interventions:   Device: Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation;   Device: Standard Advanced Cardiac Life Support (ACLS) Resuscitation
  Sponsor:   University of Minnesota
  Recruiting
• Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

  NCT03852992

  Conditions:   Male Pattern Hair Loss;   Androgenetic Alopecia;   Male Pattern Baldness
  Interventions:   Drug: Post-Laser Minoxidil 2%;   Drug: At-Home Minoxidil 5%;   Device: Laser;   Drug: Post-laser 5mg minoxidil;   Drug: Post-laser 10mg minoxidil;   Drug: Post-laser 20mg minoxidil
  Sponsor:   University of Minnesota
  Recruiting
• Cystic Fibrosis and Cognitive Function

  NCT03820349

  Condition:   Cystic Fibrosis
  Intervention:  
  Sponsor:   University of Minnesota
  Recruiting
• Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis

  NCT03779139

  Conditions:   Chronic Pancreatitis;   Diabetes Mellitus;   Islet Cell Transplantation
  Interventions:   Procedure: Intrahepatic islets and islets in the omental pouch;   Procedure: Intrahepatic islets alone;   Other: Normal Volunteers
  Sponsor:   University of Minnesota
  Recruiting
• Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg

  NCT03762915

  Conditions:   SRP;   Minocycline HCl Microspheres;   Biomarkers
  Intervention:   Drug: minocycline HCl microspheres
  Sponsors:   University of Minnesota;   Bausch Health Companies, INC.
  Recruiting
• Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures

  NCT03744728

  Condition:   Bloodstream Infection
  Interventions:   Diagnostic Test: Accelerate PhenoTest™ BC kit;   Diagnostic Test: Standard of Care
  Sponsor:   Accelerate Diagnostics, Inc.
  Recruiting
• Trial of Indole-3-Carbinol and Silibinin

  NCT03687073

  Condition:   Smoking
  Interventions:   Drug: Indole-3-Carbinol;   Drug: Silibinin;   Drug: Silibin
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• A Study of FMT in Patients With AML Allo HSCT in Recipients

  NCT03678493

  Conditions:   Acute Myeloid Leukemia;   Allogeneic Hematopoietic Cell Transplantation
  Interventions:   Biological: Fecal Microbiota Transplant (FMT);   Other: Placebo
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Spectroscopic Magnetic Resonance Imaging of Glioma

  NCT03677999

  Condition:   Brain Tumor-Glioma
  Intervention:   Diagnostic Test: MEGA-PRESS sequence Magnetic Resonance Spectroscopy
  Sponsor:   University of Minnesota
  Recruiting
• Neuromodulation Augmented Cognitive Training to Improve Cognitive Flexibility in Anorexia Nervosa

  NCT03647943

  Conditions:   Active tDCS;   Sham tDCS
  Interventions:   Device: Transcranial direct current stimulation;   Device: Sham transcranial direct current stimulation
  Sponsor:   University of Minnesota
  Recruiting
• mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management

  NCT03612271

  Condition:   Hypertension
  Intervention:   Behavioral: mGlide
  Sponsors:   University of Minnesota;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Improving Self-Efficacy, Resolving Inflammaging Allo HSCT Survivors in Personal Training

  NCT03609203

  Condition:   Allogeneic HCT Survivors
  Interventions:   Other: 10 Weeks of Strength Trailing;   Other: Group Nutrition Discussion: week 1, week 5 and week 10
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Liposome Bupivacaine in Interscalene Block for Rotator Cuff Repair

  NCT03587584

  Condition:   Acute Pain
  Interventions:   Drug: liposomal bupivacaine;   Drug: Bupivacaine
  Sponsor:   University of Minnesota
  Recruiting
• Effect of Constraint-Induced Gaming Therapy in an Acute Care Setting

  NCT03578536

  Condition:   Stroke
  Intervention:   Device: Recovery Rapids
  Sponsor:   VA Office of Research and Development
  Recruiting
• Splenic Embolization for Portal Hypertension

  NCT03532750

  Condition:   Portal Hypertension
  Interventions:   Device: Particle;   Device: Coil
  Sponsor:   University of Minnesota
  Recruiting
• Role of CGMS Usage in Predicting Risk for Hypoglycemia

  NCT03481530

  Conditions:   Type 2 Diabetes Mellitus;   Hypoglycemia
  Intervention:   Device: Continuing Glucose Monitor System
  Sponsor:   University of Minnesota
  Recruiting
• The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa

  NCT03414112

  Condition:   Anorexia Nervosa
  Intervention:   Biological: Intranasal oxytocin
  Sponsors:   University of Minnesota;   Klarman Foundation
  Recruiting
• Post Acute Cardiac Event Smoking (PACES) Study

  NCT03413423

  Conditions:   Acute Coronary Syndrome;   Tobacco Use
  Interventions:   Behavioral: BAT-CS;   Behavioral: Smoking Cessation and Health & Wellness
  Sponsors:   Hennepin Healthcare Research Institute.;   Minneapolis Heart Institute Foundation;   The Miriam Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   University of Minnesota
  Recruiting
• Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)

  NCT03410277

  Condition:   Diabetes Mellitus, Type 1
  Intervention:   Other: Experimental hypoglycemia
  Sponsor:   University of Minnesota
  Recruiting
• Post C-Section Pain Control Using EXPAREL

  NCT03377595

  Condition:   Pain, Postoperative
  Intervention:   Drug: Exparel
  Sponsor:   University of Minnesota
  Recruiting
• Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

  NCT03346668

  Conditions:   Scarring Alopecia;   Frontal Fibrosing Alopecia;   Lichen Planopilaris;   Central Centrifugal Cicatricial Alopecia;   Central Centrifugal Scarring Alopecia
  Intervention:   Drug: Topical gabapentin
  Sponsor:   University of Minnesota
  Recruiting
• Cortical Spreading Depolarization After Severe Traumatic Brain Injury

  NCT03321370

  Condition:   Traumatic Brain Injury
  Intervention:   Diagnostic Test: Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention
  Sponsor:   Hennepin County Medical Center, Minneapolis
  Recruiting
• Assessment of Markers of Stress in Acute Ischemic Stroke With Hyperglycemia

  NCT03318679

  Conditions:   Ischemic Stroke;   Hyperglycemia
  Intervention:   Other: No intervention is planned.
  Sponsor:   University of Minnesota
  Recruiting
• Assessing Leg Control in People With Chronic Stroke

  NCT03271463

  Condition:   Chronic Stroke
  Intervention:   Behavioral: Selective Control Assessment of Lower Extremity (SCALE)
  Sponsor:   University of Minnesota
  Recruiting
• Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin

  NCT03259581

  Conditions:   Hepatocellular Carcinoma;   Bilirubinemia
  Intervention:   Combination Product: Transarterial chemoembolization
  Sponsor:   University of Minnesota
  Recruiting
• Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract

  NCT03218085

  Conditions:   HIV/AIDS;   Menopause;   Inflammation Vagina
  Interventions:   Drug: Tenofovir;   Drug: Emtricitabine
  Sponsors:   University of Minnesota;   American College of Clinical Pharmacy
  Recruiting
• GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE™) for High Risk Heme Malignancies

  NCT03214666

  Conditions:   High-risk Myelodysplastic Syndromes;   Acute Myelogenous Leukemia;   Systemic Mastocytosis;   Mast Cell Leukemia
  Interventions:   Drug: GTB-3550 TriKE™ Phase I;   Drug: GTB-3550 TriKE™ Phase II
  Sponsor:   GT Biopharma, Inc.
  Recruiting
• Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

  NCT03213964

  Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
  Interventions:   Biological: FATE-NK100;   Drug: Interleukin-2
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy

  NCT03195868

  Conditions:   Neuropathy;   Neuropathy, Diabetic;   Neuropathy Toxic
  Intervention:   Device: Realief Therapy
  Sponsor:   University of Minnesota
  Recruiting
• Observational Study of Solid Organ Transplantation Utilizing HIV-Positive Donors in HIV-Positive Recipients

  NCT03170414

  Conditions:   HIV;   Awaiting Organ Transplant
  Intervention:  
  Sponsor:   University of Minnesota
  Recruiting
• Naloxone, Hypoglycemia and Exercise

  NCT03149770

  Condition:   Diabetes Mellitus, Type 1
  Interventions:   Drug: Naloxone;   Drug: Placebo
  Sponsor:   University of Minnesota
  Recruiting
• Leg Exercise During ECMO

  NCT03135210

  Condition:   Refractory Respiratory Failure
  Interventions:   Other: Open-Chain Leg Exercise;   Device: Closed-Chain Leg Exercise
  Sponsor:   University of Minnesota
  Recruiting
• Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Project 1 Aim 2 and 3

  NCT03079037

  Condition:   Parkinson Disease
  Intervention:   Device: Stimulation
  Sponsor:   University of Minnesota
  Recruiting
• Stress Reactivity as a Determinant in Co-occurring Alcohol Use and Anxiety Disorder: Diagnosis and Alcohol Use Outcomes

  NCT03056872

  Conditions:   Alcohol Use Disorder;   Anxiety Disorder/Anxiety State;   Stress Disorder;   Hypothalamic Pituitary Adrenal;   Drinking to Cope
  Intervention:  
  Sponsors:   University of Minnesota;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  Recruiting
• IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

  NCT03054909

  Conditions:   FIGO Stage III and IV Ovarian Cancer;   FIGO Stage III and IV Fallopian Tube Cancer;   FIGO Stage III Primary Peritoneal Cancer
  Interventions:   Biological: ALT-803 Subcutaneous;   Biological: ALT-803 Intraperitoneal
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

  NCT03005379

  Condition:   Clostridium Difficile Infection
  Interventions:   Drug: Fecal Microbiota Therapy (FMT);   Drug: Placebo
  Sponsor:   VA Office of Research and Development
  Recruiting
• Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

  NCT02989844

  Conditions:   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS)
  Intervention:   Drug: N-803
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Assessment of Brain Activities in Cervical Dystonia

  NCT02959645

  Condition:   Cervical Dystonia
  Intervention:  
  Sponsor:   University of Minnesota
  Recruiting
• Graded Motor Imagery for Women at Risk for Developing Type I CRPS Following Closed Treatment of Distal Radius Fractures

  NCT02957240

  Conditions:   Musculoskeletal Pain;   Fractures, Closed;   Distal Radius Fracture;   Complex Regional Pain Syndromes
  Interventions:   Behavioral: Standard Care;   Behavioral: Motor Representation Techniques
  Sponsors:   University of Minnesota;   American Hand Therapy Foundation;   Fairview Health Services
  Recruiting
• Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

  NCT02930889

  Condition:   Benign Prostatic Hyperplasia
  Intervention:   Device: Prostate Artery Embolization
  Sponsor:   University of Minnesota
  Recruiting
• The Residential Care Transition Module

  NCT02915939

  Conditions:   Alzheimer Disease;   Dementia
  Intervention:   Behavioral: The Residential Care Transition Module
  Sponsors:   University of Minnesota;   Johns Hopkins University;   NYU Langone Health;   Benjamin Rose Institute;   Emory University
  Recruiting
• Measurement of Glucose Metabolism in Humans: Effect of Recurrent Hypoglycemia on Hypothalamic GABA

  NCT02829593

  Conditions:   Type 1 Diabetes;   Healthy
  Intervention:   Other: hypoglycemia (low blood sugar) and MRI
  Sponsor:   University of Minnesota
  Recruiting
• Anti-inflammatory Therapy to Improve Outcomes After TPIAT

  NCT02713997

  Condition:   Pancreatitis, Chronic; Diabetes; Transplant
  Interventions:   Drug: etanercept;   Drug: Alpha 1-Antitrypsin
  Sponsors:   University of Minnesota;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

  NCT02636283

  Condition:   Peripheral Arterial Disease
  Interventions:   Drug: Entresto;   Drug: Placebo group
  Sponsors:   University of Minnesota;   American Heart Association
  Recruiting
• Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MRI

  NCT02550366

  Condition:   Cardiac Disease
  Intervention:   Drug: MRI Contrast
  Sponsor:   University of Minnesota
  Recruiting
• Beta-blockers in Pulmonary Arterial Hypertension

  NCT02507011

  Condition:   Pulmonary Arterial Hypertension
  Interventions:   Drug: Carvedilol;   Drug: Placebo
  Sponsor:   University of Minnesota
  Recruiting
• Predicting Rupture of AAA by Anatomic and Hemodynamic Markers

  NCT02463760

  Condition:   Aortic Aneurysm, Abdominal
  Intervention:   Other: Medical imaging
  Sponsor:   University of Minnesota
  Recruiting
• The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive Pulmonary Disease

  NCT02252588

  Condition:   Chronic Obstructive Pulmonary Disease
  Interventions:   Drug: Chlorhexidine;   Other: Placebo
  Sponsors:   University of Minnesota;   Veterans Medical Research Foundation;   Flight Attendant Medical Research Institute
  Recruiting
• Mapping Chemical and Microbiological Heterogeneity Throughout Explanted Cystic Fibrosis Lung Specimens

  NCT02128711

  Condition:   Cystic Fibrosis
  Intervention:  
  Sponsors:   University of Minnesota;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Spinal Cord Stimulation to Treat Hypertension

  NCT02828436

  Condition:   Hypertension
  Interventions:   Device: Precision Spectra System;   Behavioral: Exercise Intervention
  Sponsor:   University of Minnesota
  Recruiting
• Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients

  NCT04083690

  Condition:   Heart Failure, Systolic
  Intervention:   Device: Reprogramming of CRT Device Settings to Optimal Electrical Synchrony
  Sponsor:   Allina Health System
  Recruiting
• Safety and Efficacy Study of the SoundBite™ Crossing System With ACTIVE Wire in Coronary CTOs.

  NCT03521804

  Condition:   Chronic Total Occlusion of Coronary Artery
  Intervention:   Device: SoundBite™ Crossing System Active Wire 14
  Sponsors:   SoundBite Medical Solutions, Inc.;   ethica Clinical Research Inc.;   Cardiovascular Research Foundation, New York
  Recruiting
• Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

  NCT02583672

  Condition:   Gaucher Disease Type 1
  Intervention:   Drug: N-acetylcysteine
  Sponsors:   University of Minnesota;   Rare Diseases Clinical Research Network;   National Center for Advancing Translational Science (NCATS);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Neurological Disorders and Stroke (NINDS);   Lysosomal Disease Network
  Recruiting
• Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes

  NCT03944616

  Condition:   Type 2 Diabetes
  Interventions:   Behavioral: Diet Beverage;   Behavioral: Water
  Sponsors:   University of California, Irvine;   University of Minnesota;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Pioglitazone for the Treatment of Alcohol Use Disorder

  NCT03864146

  Condition:   Alcohol Use Disorder
  Intervention:   Behavioral: Brief Behavioral Compliance Enhancement Treatment
  Sponsor:   VA Office of Research and Development
  Recruiting
• Seven vs. 14 Days Treatment for Male Urinary Tract Infection

  NCT01994538

  Condition:   Urinary Tract Infections
  Interventions:   Other: Longer therapy duration;   Other: Shorter therapy duration
  Sponsor:   VA Office of Research and Development
  Recruiting
• Dysphonia, Distress, and Perceived Control: Technology Based Assessment and Intervention

  NCT03576365

  Conditions:   Functional Dysphonia;   Voice Disorders;   Dysphonia
  Interventions:   Behavioral: VOICE Intervention Arm;   Behavioral: Information-Only Arm
  Sponsors:   University of Minnesota;   National Institute on Deafness and Other Communication Disorders (NIDCD)
  Recruiting
• Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS

  NCT03202017

  Condition:   Amyotrophic Lateral Sclerosis
  Interventions:   Procedure: Expiratory Muscle Strength Training (EMST);   Procedure: EMST + Lung Volume Recruitment (LVR)
  Sponsor:   University of Minnesota
  Recruiting
• Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

  NCT01562626

  Conditions:   Tumors;   Neoplasms;   Cancer
  Interventions:   Drug: APS001F;   Drug: Flucytosine (5-FC);   Drug: 10% maltose
  Sponsor:   Anaeropharma Science, Inc.
  Recruiting
• Improving Outcome for Family Caregivers of Older Adults With Complex Conditions: The Adult Day Plus (ADS Plus) Program

  NCT02927821

  Condition:   Stress
  Intervention:   Behavioral: ADS Plus
  Sponsors:   Johns Hopkins University;   University of Minnesota;   National Institute on Aging (NIA)
  Recruiting
• Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

  NCT02356159

  Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
  Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability

  NCT02002819

  Condition:   Alzheimer's Disease
  Intervention:   Drug: levetiracetam
  Sponsor:   University of Minnesota
  Recruiting
• EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture

  NCT03955458

  Conditions:   Hip Fractures;   Intertrochanteric Fractures
  Interventions:   Drug: EXPAREL;   Drug: Ropivacaine;   Drug: Bupivacaine Hydrochloride
  Sponsor:   Pacira Pharmaceuticals, Inc
  Recruiting
• Non-Invasive and Non-Contact Intracranial Pressure Waveform Recording Using Dynamic Video Ophthalmoscopy

  NCT04046523

  Condition:   Intracranial Pressure Increase
  Intervention:   Device: Video ophthalmoscope
  Sponsor:   University of Minnesota
  Recruiting
• Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

  NCT03557749

  Conditions:   Immune and Microbial Reconstitution;   Systemic Viral Infection;   Acute-graft-versus-host Disease;   Chronic Graft-versus-host-disease;   Recurrent Malignancy;   Cytokine Release Syndrome;   Allogenic Related Donors;   Cell Therapy/Immunotherapy Patients
  Interventions:   Diagnostic Test: Blood Sample;   Diagnostic Test: Stool Sample;   Diagnostic Test: Urine Sample;   Diagnostic Test: Bronchoalveolar Lavage (BAL) fluid;   Diagnostic Test: Gastrointestinal biopsy x 2-4;   Diagnostic Test: Skin biopsy;   Diagnostic Test: Skin, mouth, and/or ocular swab;   Diagnostic Test: Apheresis Product;   Diagnostic Test: Final cellular product
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• International PPB/DICER1 Registry

  NCT03382158

  Conditions:   Pleuropulmonary Blastoma;   Sertoli-Leydig Cell Tumor;   DICER1 Syndrome;   Cystic Nephroma;   Wilms Tumor;   Pineoblastoma;   Renal Sarcoma;   Nodular Hyperplasia of Thyroid;   Nasal Chondromesenchymal Hamartoma;   Ciliary Body Medulloepithelioma;   Neuroblastoma;   Pituitary Cancer;   Embryonal Rhabdomyosarcoma
  Intervention:  
  Sponsors:   Children's Hospitals and Clinics of Minnesota;   Children's Research Institute;   Washington University School of Medicine;   ResourcePath, LLC;   Beijing Children's Hospital;   University of Cambridge;   Emory University;   Dana-Farber Cancer Institute
  Recruiting
• Auto Stem Cell Transplant for Lymphoma Patients

  NCT03125642

  Conditions:   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
  Interventions:   Drug: Etoposide;   Drug: BCNU;   Drug: AraC;   Drug: Melphalan;   Procedure: Peripheral blood stem cell transplantation;   Biological: G-CSF;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic

  NCT02988466

  Condition:   Hematologic Malignancies
  Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis;   Biological: Haplo HCT ≥55 and < 65 years old;   Biological: Haplo HCT ≥65 and ≤75 years old
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME

  NCT02973815

  Conditions:   Obesity, Childhood;   Physical Activity;   Food Intake;   Rural Health
  Intervention:   Behavioral: NU-HOME Intervention
  Sponsors:   University of Minnesota;   Allina Health System;   Minneapolis Heart Institute Foundation
  Recruiting
• Clinical Performance of a New Esthetic, Self-ligating Orthodontic Bracket

  NCT02959671

  Condition:   Malocclusion
  Intervention:   Device: Lower Anterior EXD-952 Self-ligating Brackets
  Sponsors:   University of Minnesota;   3M Oral Care
  Recruiting
• UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

  NCT02722668

  Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
  Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Exemestane in Post-Menopausal Women With NSCLC

  NCT02666105

  Condition:   Non-Small Cell Lung Cancer
  Intervention:   Drug: Exemestane
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Allo HSCT Using RIC for Hematological Diseases

  NCT02661035

  Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
  Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

  NCT02525029

  Condition:   Graft vs Host Disease
  Intervention:   Drug: Pregnyl®
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Gulf War Illness Inflammation Reduction Trial

  NCT02506192

  Conditions:   Chronic Inflammation;   Chronic Pain;   Fatigue;   Cognitive Impairment
  Interventions:   Drug: Delayed-Release Prednisone;   Drug: Placebo
  Sponsors:   Minneapolis Veterans Affairs Medical Center;   United States Department of Defense
  Recruiting
• Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

  NCT02162420

  Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
  Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Stem Cell Transplant;   Drug: Anti-thymocyte globulin
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

  NCT02161783

  Conditions:   Primary Graft Failure;   Secondary Graft Failure
  Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Hematopoietic stem cell infusion
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

  NCT01166009

  Conditions:   Autologous Stem Cell Transplantation;   Allogeneic Stem Cell Transplantation;   Solid Tumors;   Blood Cancers
  Intervention:  
  Sponsor:   Center for International Blood and Marrow Transplant Research
  Recruiting
• Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

  NCT00630565

  Condition:   Leukemia
  Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: bone marrow transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Alport Syndrome Treatments and Outcomes Registry

  NCT00481130

  Condition:   Alport Syndrome
  Intervention:  
  Sponsor:   University of Minnesota
  Recruiting
• Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

  NCT00432094

  Conditions:   Childhood Germ Cell Tumor;   Ovarian Cancer;   Teratoma
  Interventions:   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide;   Drug: paclitaxel;   Drug: thiotepa;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: Mesna;   Biological: filgrastim
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations

  NCT03651830

  Condition:   Amputation
  Interventions:   Device: Prosthetic Foot Emulator;   Device: Commercially available prosthetic feet
  Sponsors:   Seattle Institute for Biomedical and Clinical Research;   VA Puget Sound Health Care System;   Minneapolis Veterans Affairs Medical Center;   Brooke Army Medical Center;   Stanford University;   University of Washington
  Recruiting
• Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain

  NCT03581123

  Conditions:   Acute Pain;   Low Back Pain, Mechanical
  Interventions:   Behavioral: Supported-Self Management (SSM);   Other: Spinal Manipulation Therapy (SMT);   Combination Product: SMT + SSM;   Drug: Standard Medical Care (SMC)
  Sponsors:   University of Minnesota;   University of Pittsburgh;   University of Washington;   University of North Texas Health Science Center;   Oregon Health and Science University;   Duke University
  Recruiting
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

  NCT04106167

  Conditions:   Advanced Solid Tumor;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small-cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
  Intervention:   Genetic: Allogeneic natural killer (NK) cell
  Sponsor:   Fate Therapeutics
  Recruiting
• UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)

  NCT04075656

  Condition:   Idiopathic Nephrotic Syndrome
  Interventions:   Behavioral: Standard of Care;   Behavioral: UrApp
  Sponsors:   Emory University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

  NCT03841110

  Conditions:   Advanced Solid Tumors;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
  Interventions:   Drug: FT500;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Atezolizumab;   Drug: Cyclophosphamide;   Drug: Fludarabine
  Sponsor:   Fate Therapeutics
  Recruiting
• Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

  NCT03732950

  Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Intervention:   Biological: Pembrolizumab
  Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma

  NCT03554083

  Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  Interventions:   Drug: Atezolizumab;   Drug: Cobimetinib;   Drug: Vemurafenib
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI);   Genentech, Inc.;   Stand Up To Cancer
  Recruiting
• CAP-Ketamine for Antidepressant Resistant PTSD

  NCT02655692

  Conditions:   PTSD;   Posttraumatic Stress Disorder
  Interventions:   Drug: Ketamine;   Drug: Placebo
  Sponsors:   VA Office of Research and Development;   The University of Texas Health Science Center at San Antonio;   Brooke Army Medical Center;   Minneapolis Veterans Affairs Medical Center
  Recruiting
• Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

  NCT03663933

  Conditions:   Lymphoproliferative Disorders;   Autoimmune Lymphoproliferative;   Primary T-cell Immunodeficiency Disorders;   Immune System Diseases;   Common Variable Immunodeficiency
  Interventions:   Drug: Immunosuppression Only Conditioning (IOC);   Drug: Reduced Intensity Conditioning (RIC);   Drug: GVHD Prophylaxis;   Procedure: Allogeneic HSC
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Improving Veteran Adherence to Treatment for PTSD Through Partnering With Families

  NCT03256227

  Condition:   Posttraumatic Stress Disorder
  Interventions:   Behavioral: Family Supported Prolonged Exposure;   Behavioral: Standard Prolonged Exposure
  Sponsor:   VA Office of Research and Development
  Recruiting
• D2D Normative Data for Remote Assessments

  NCT03206775

  Condition:   Cognition
  Interventions:   Behavioral: Cognitive Assessments (Phase 1);   Behavioral: Cognitive Battery A (Phase 2);   Behavioral: Cognitive Battery B (Phase 2);   Behavioral: Cognitive Battery C (Phase 2)
  Sponsors:   University of Minnesota;   University of California, San Francisco;   Posit Science Corporation
  Recruiting
• A Phase 1 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD

  NCT03604692

  Condition:   Chronic Graft-versus-host-disease
  Intervention:   Drug: SNDX-6352
  Sponsor:   Syndax Pharmaceuticals
  Recruiting
• A Study of CNSA-001 in Primary Tetrahydrobiopterin Deficient Patients With Hyperphenylalaninemia

  NCT03519711

  Conditions:   BH4 Deficiency;   Hyperphenylalaninemia, Non-Phenylketonuric
  Intervention:   Drug: CNSA-001
  Sponsor:   Censa Pharmaceuticals, Inc.
  Recruiting
• NAN-101 in Patients With Class III Heart Failure

  NCT04179643

  Conditions:   Congestive Heart Failure;   Heart Failure;   Heart Disease, Ischemic;   Cardiovascular Diseases;   Heart Failure, Systolic;   Heart Failure，Congestive;   Heart Arrhythmia;   Heart Failure, Diastolic;   Heart; Complications
  Intervention:   Biological: 3 x 10e13vg NAN-101
  Sponsor:   Asklepios Biopharmaceutical, Inc.
  Recruiting
• walk2Wellness: Long-term Effects of Walkasins® Wearable Sensory Prosthesis

  NCT03538756

  Conditions:   Sensory Peripheral Neuropathy;   Balance; Distorted;   Sensation Disorders
  Intervention:   Device: Walkasins
  Sponsor:   RxFunction Inc.
  Recruiting
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

  NCT03319459

  Conditions:   HER2 Positive Gastric Cancer;   Colorectal Cancer;   Head and Neck Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   Advanced Solid Tumors;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreatic Cancer;   Melanoma
  Interventions:   Drug: FATE-NK100;   Drug: Cetuximab;   Drug: Trastuzumab
  Sponsor:   Fate Therapeutics
  Recruiting
• Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

  NCT03300557

  Conditions:   Atypical Hyperplasia;   Endometrial Intraepithelial Neoplasia;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
  Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Other: Pharmacokinetic Study;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney

  NCT02210650

  Condition:   Ureteral Stones
  Interventions:   Procedure: Ureteral stone removal;   Procedure: Asymptomatic kidney stones and ureteral stone removed
  Sponsors:   Indiana Kidney Stone Institute;   University of Washington Medical Center Department of Urology (Seattle, WA);   VA Puget Sound Health Care System
  Recruiting
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

  NCT03016741

  Conditions:   Castration-Resistant Prostatic Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer;   Hormone-Refractory Prostate Cancer
  Interventions:   Biological: GnRH agonist/antagonist;   Drug: Prednisone;   Drug: Abiraterone Acetate;   Drug: Enzalutamide
  Sponsor:   Northwestern University
  Recruiting
• Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

  NCT02876640

  Conditions:   Early-Stage Breast Carcinoma;   Invasive Breast Carcinoma
  Interventions:   Drug: Retinoid 9cUAB30;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• CoQ10 in Gulf War Illness

  NCT02865460

  Conditions:   Gulf War Illness;   Chronic Fatigue;   Ubiquinol;   Coenzyme Q10
  Interventions:   Drug: Ubiquinol;   Drug: Placebo
  Sponsor:   VA Office of Research and Development
  Recruiting
• Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

  NCT03502746

  Condition:   Mesothelioma, Malignant
  Interventions:   Drug: Nivolumab;   Drug: Ramucirumab
  Sponsors:   Arkadiusz Z. Dudek, MD;   HealthPartners Institute Regions Cancer Care Center;   Eli Lilly and Company;   Bristol-Myers Squibb
  Recruiting
• Genetic Modifiers of Cystic Fibrosis Related Diabetes

  NCT01113216

  Condition:   Cystic Fibrosis Related Diabetes
  Intervention:  
  Sponsors:   Johns Hopkins University;   Cystic Fibrosis Foundation;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Minnesota;   Northwestern University
  Recruiting
• Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure

  NCT03056157

  Conditions:   Post-traumatic Stress Disorder;   Moral Injury;   Traumatic Loss
  Interventions:   Behavioral: Adaptive Disclosure for Moral Injury and Loss;   Behavioral: Present Centered Therapy
  Sponsors:   VA Office of Research and Development;   Minneapolis Veterans Affairs Medical Center;   San Francisco Veterans Affairs Medical Center;   San Diego Veterans Healthcare System
  Recruiting
• Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

  NCT02867384

  Condition:   Graft vs. Host Disease
  Interventions:   Drug: Obinutuzumab;   Drug: Placebo
  Sponsors:   Dana-Farber Cancer Institute;   Roche-Genentech
  Recruiting
• Mindful Movement for Physical Activity and Wellbeing in Older Adults- A Hybrid Effectiveness-Implementation Study

  NCT03929393

  Conditions:   Physical Inactivty;   Wellbeing;   Mindfulness
  Interventions:   Behavioral: Mindful Movement;   Other: Keys to Health & Wellbeing
  Sponsors:   University of Minnesota;   YMCA;   National Center for Complementary and Integrative Health (NCCIH)
  Recruiting
• Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

  NCT03737981

  Condition:   Chronic Lymphocytic Leukemia
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Observation;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

  NCT03633331

  Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Dried Blood Spot Testing of CMV Detection in HCT Recipients

  NCT03910478

  Condition:   Cytomegalovirus Infection
  Interventions:   Device: DBS Self-Collection Kit;   Other: Standard Control Strategy
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis

  NCT03042104

  Conditions:   Aortic Stenosis;   Heart Diseases
  Intervention:   Device: Edwards SAPIEN 3 THV
  Sponsor:   Edwards Lifesciences
  Recruiting
• Diuretic Comparison Project

  NCT02185417

  Condition:   Hypertension
  Interventions:   Drug: Hydrochlorothiazide (HCTZ);   Drug: Chlorthalidone
  Sponsor:   VA Office of Research and Development
  Recruiting
• Mepo for EoE Study

  NCT03656380

  Conditions:   EoE;   Eosinophilic Esophagitis
  Interventions:   Drug: Mepolizumab 300 mg;   Drug: Mepolizumab 100 mg;   Other: Placebo
  Sponsors:   University of North Carolina, Chapel Hill;   GlaxoSmithKline;   University of Utah;   Northwestern University;   Minnesota Gastroenterology, P.A.
  Recruiting
• A Registry of Patients With Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs)

  NCT03941379

  Conditions:   Choroidal Melanoma;   Indeterminate Lesions of Eye
  Intervention:  
  Sponsor:   Aura Biosciences
  Recruiting
• Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

  NCT03557385

  Condition:   Percutaneous Coronary Intervention
  Interventions:   Drug: Iopamidol;   Drug: adenosine;   Device: Navvus® Catheter;   Device: CVi® Contrast Delivery System
  Sponsors:   Duke University;   Acist Medical Systems
  Recruiting
• Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

  NCT02396134

  Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Hodgkin Lymphoma;   Adult Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   HLA-A*0201 Positive Cells Present;   Myelodysplastic Syndrome;   Adult Lymphoblastic Lymphoma;   Chronic Lymphocytic Leukemia;   Myelofibrosis;   Myeloproliferative Neoplasm
  Interventions:   Biological: CMVpp65-A*0201 peptide vaccine;   Other: Placebo;   Other: Laboratory Biomarker Analysis
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Wellclub Shoulder Therapy Outcome Validation

  NCT02954185

  Condition:   Shoulder Pain
  Interventions:   Device: WellClub;   Behavioral: Standard Therapy
  Sponsors:   University of Minnesota;   Fairview Sports Physical Therapy Program
  Recruiting
• Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

  NCT03087708

  Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
  Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

  NCT03701282

  Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

  NCT03578081

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

  NCT02121158

  Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
  Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal Medical Therapy
  Sponsor:   VA Office of Research and Development
  Recruiting
• Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

  NCT04114981

  Condition:   Metastatic Malignant Neoplasm in the Brain
  Interventions:   Radiation: Single Fraction Stereotactic Radiosurgery;   Radiation: Fractionated Stereotactic Radiosurgery;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688

  Condition:   Colorectal Adenocarcinoma
  Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Irinotecan;   Dietary Supplement: Cholecalciferol;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

  NCT04071457

  Condition:   Multiple Myeloma
  Interventions:   Drug: Lenalidomide;   Drug: Daratumumab/rHuPH20
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Janssen, LP;   Adaptive
  Recruiting
• Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors

  NCT03996265

  Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Cancer Fatigue;   Cancer Survivor;   Complete Remission;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
  Interventions:   Drug: Bupropion Hydrochloride Controlled-release;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gary Morrow;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Guiding Treatment for Patients With Brain Metastases

  NCT03994796

  Conditions:   CDK Gene Mutation;   Metastatic Malignant Neoplasm in the Brain;   Metastatic Malignant Solid Neoplasm;   NTRK Family Gene Mutation;   PI3K Gene Mutation;   ROS1 Gene Mutation
  Interventions:   Drug: Abemaciclib;   Drug: PI3K Inhibitor GDC-0084;   Drug: Entrectinib
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Genentech, Inc.
  Recruiting
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

  NCT03984448

  Conditions:   Diffuse Large B-Cell Lymphoma;   Double-Expressor Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474

  Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

  NCT03944941

  Conditions:   Skin Squamous Cell Carcinoma;   Metastatic Skin Cancer
  Interventions:   Drug: Avelumab;   Drug: Cetuximab
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  NCT03937635

  Condition:   Smoldering Plasma Cell Myeloma
  Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Tenofovir Alafenamide in Preventing Liver Complications in Participants With Current or Past Hepatitis B Virus Who Are Receiving Anti-Cancer Therapy for Solid Tumors

  NCT03887702

  Conditions:   Hepatitis B Virus Positive;   Malignant Solid Neoplasm
  Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Drug: Tenofovir Alafenamide
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382

  Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

  NCT03839940

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Dexamethasone;   Other: Placebo;   Other: Questionnaire;   Other: Quality-of-Life Assessment;   Drug: Everolimus
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer

  NCT03811015

  Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
  Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414

  Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)

  NCT03737994

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer

  NCT03712605

  Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
  Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

  NCT03707574

  Conditions:   Advanced Malignant Neoplasm;   Advanced Melanoma;   Advanced Renal Cell Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8
  Intervention:   Procedure: Biospecimen Collection
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

  NCT03701308

  Condition:   Acute Myeloid Leukemia
  Interventions:   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Uproleselan
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

  NCT03698019

  Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

  NCT03694002

  Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia

  NCT03654768

  Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

  NCT03609216

  Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
  Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

  NCT03499808

  Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
  Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

  NCT03475186

  Conditions:   Glioblastoma;   Radiotherapy; Complications;   Cognitive Decline;   Chemoradiation
  Intervention:   Drug: Ramipril
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223

  Condition:   Acute Coronary Syndrome
  Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
  Sponsor:   CSL Behring
  Recruiting
• S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

  NCT03418961

  Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

  NCT03414970

  Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
  Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

  NCT03375320

  Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
  Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

  NCT03371719

  Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
  Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

  NCT03330405

  Condition:   Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
  Interventions:   Drug: Avelumab Phase 1b;   Drug: Talazoparib Phase 1b;   Drug: Avelumab Phase 2;   Drug: Talazoparib Phase 2
  Sponsor:   Pfizer
  Recruiting
• Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer

  NCT03304639

  Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
  Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

  NCT03224767

  Conditions:   BRAF V600E Mutation Present;   Papillary Craniopharyngioma
  Interventions:   Drug: Vemurafenib;   Drug: Cobimetinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

  NCT03180294

  Conditions:   Breast Carcinoma;   Cervical Carcinoma;   Ovarian Carcinoma;   Postmenopausal;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
  Interventions:   Drug: Bupropion Hydrochloride;   Other: Placebo
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection

  NCT03061305

  Conditions:   Cancer;   Adult Solid Tumor;   Lymphoma
  Intervention:  
  Sponsor:   Strata Oncology
  Recruiting
• Stepped-Care Telehealth for Distress in Rural Cancer Survivors

  NCT03060096

  Conditions:   Anxiety;   Depressive Symptoms;   Sleep Disturbance;   Recurrent Disease;   Fatigue;   Quality of Life;   Cancer
  Interventions:   Other: Severe Anxiety/depression: High Intensity Stepped Care;   Other: Moderate Anxiety/depression: Low Intensity Stepped care;   Other: Enhanced Usual Care Control
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934

  Condition:   Metastatic Castration Resistant Prostate Cancer
  Interventions:   Drug: Rucaparib;   Drug: Abiraterone acetate or Enzalutamide or Docetaxel
  Sponsors:   Clovis Oncology, Inc.;   Foundation Medicine
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

  NCT02822573

  Conditions:   Cognitive Dysfunction;   Memory Impairment
  Interventions:   Drug: Donepezil 5 mg;   Drug: Placebo
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

  NCT02775851

  Condition:   Desmoplastic Melanoma
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

  NCT02761057

  Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

  NCT02744092

  Conditions:   Cancer;   Venous Thromboembolism;   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE);   Blood Clot
  Interventions:   Drug: Rivaroxaban;   Drug: Apixaban;   Drug: Edoxaban;   Drug: Dabigatran;   Drug: Warfarin;   Drug: Dalteparin;   Drug: Enoxaparin;   Drug: Fondaparinux
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute
  Recruiting
• Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  NCT02734537

  Conditions:   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant;   Lip and Oral Cavity Squamous Cell Carcinoma;   p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting